Financials Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:48:52 2024-05-20 pm EDT 5-day change 1st Jan Change
9.665 USD +0.99% Intraday chart for Amicus Therapeutics, Inc. +7.25% -31.68%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,482 6,017 3,218 3,430 4,161 2,835 - -
Enterprise Value (EV) 1 2,179 5,923 3,125 3,529 4,263 3,016 2,919 2,583
P/E ratio -6.58 x -21.6 x -12.6 x -14.9 x -27.8 x -45.4 x 43.5 x 12.6 x
Yield - - - - - - - -
Capitalization / Revenue 13.6 x 23.1 x 10.5 x 10.4 x 10.4 x 5.56 x 4.41 x 3.34 x
EV / Revenue 12 x 22.7 x 10.2 x 10.7 x 10.7 x 5.91 x 4.54 x 3.04 x
EV / EBITDA -7.28 x -24.9 x -15.6 x -17.1 x -61.5 x -689 x 23.7 x 8.83 x
EV / FCF -8.06 x -25 x -15.1 x -20.7 x -55.7 x 569 x 14.1 x 9.29 x
FCF Yield -12.4% -3.99% -6.6% -4.83% -1.8% 0.18% 7.09% 10.8%
Price to Book 5.22 x 21.1 x 10.5 x 27.9 x 26.1 x 12.8 x 6.84 x 3.83 x
Nbr of stocks (in thousands) 254,810 260,588 278,646 280,945 293,257 296,199 - -
Reference price 2 9.740 23.09 11.55 12.21 14.19 9.570 9.570 9.570
Announcement Date 3/2/20 3/1/21 2/24/22 3/1/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 182.2 260.9 305.5 329.2 399.4 510.2 642.8 849.3
EBITDA 1 -299.3 -238.2 -200.2 -206.8 -69.34 -4.379 123.4 292.5
EBIT 1 -304 -247 -206.4 -212.1 -77.21 -9.057 110.1 275.6
Operating Margin -166.84% -94.68% -67.57% -64.43% -19.33% -1.78% 17.13% 32.46%
Earnings before Tax (EBT) 1 -355.9 -274.3 -241.6 -242 -150.1 -59.13 73.07 245
Net income 1 -356.4 -276.9 -250.5 -236.6 -151.6 -64.14 68.33 219.2
Net margin -195.56% -106.12% -81.98% -71.85% -37.96% -12.57% 10.63% 25.81%
EPS 2 -1.480 -1.070 -0.9200 -0.8200 -0.5100 -0.2108 0.2199 0.7602
Free Cash Flow 1 -270.4 -236.5 -206.4 -170.3 -76.53 5.3 206.9 278
FCF margin -148.39% -90.66% -67.55% -51.74% -19.16% 1.04% 32.19% 32.73%
FCF Conversion (EBITDA) - - - - - - 167.66% 95.03%
FCF Conversion (Net income) - - - - - - 302.8% 126.78%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/2/20 3/1/21 2/24/22 3/1/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 82.15 78.72 80.73 81.69 88.1 86.27 94.5 103.5 115.1 110.4 121.4 133.1 145.3 142.5 156.5
EBITDA 1 -70.63 -67.31 -59.28 -32.55 -41.02 -36.38 -16.65 -14.8 -1.51 -25.57 -8.953 1.547 6.934 - -
EBIT 1 -72.15 -75.34 -60.61 -33.84 -42.33 -37.64 -18.86 -17.02 -3.692 -27.72 -3.118 5.803 14.7 9.272 20.62
Operating Margin -87.82% -95.71% -75.08% -41.42% -48.05% -43.63% -19.96% -16.45% -3.21% -25.11% -2.57% 4.36% 10.12% 6.51% 13.17%
Earnings before Tax (EBT) 1 -80.3 -81.45 -61.25 -29.26 -70.08 -53.22 -40.52 -24.7 -31.66 -43.58 -14.29 -4.275 5.803 -2.746 9.253
Net income 1 -83.28 -85.26 -62.16 -33.29 -55.86 -52.93 -43.23 -21.58 -33.84 -48.42 -16.58 -6.589 3.944 -2.746 9.253
Net margin -101.37% -108.31% -76.99% -40.75% -63.41% -61.36% -45.75% -20.85% -29.41% -43.86% -13.66% -4.95% 2.71% -1.93% 5.91%
EPS 2 -0.2900 -0.3000 -0.2100 -0.1200 -0.1900 -0.1800 -0.1500 -0.0700 -0.1100 -0.1600 -0.0542 -0.0204 0.0137 -0.008510 0.0307
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/24/22 5/9/22 8/4/22 11/7/22 3/1/23 5/10/23 8/8/23 11/8/23 2/28/24 5/9/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - 98.4 102 182 84.2 -
Net Cash position 1 303 94 93.1 - - - - 251
Leverage (Debt/EBITDA) - - - -0.4758 x -1.466 x -41.52 x 0.682 x -
Free Cash Flow 1 -270 -237 -206 -170 -76.5 5.3 207 278
ROE (net income / shareholders' equity) -87% -72.6% -84.4% -110% -107% -36.8% 16% 34.5%
ROA (Net income/ Total Assets) -43.5% -31.9% -28% -29% -5.13% 14.3% 30.5% -
Assets 1 820.1 868.4 895.8 814.7 2,957 -449.1 224 -
Book Value Per Share 2 1.870 1.090 1.100 0.4400 0.5400 0.7500 1.400 2.500
Cash Flow per Share 2 -1.040 -0.9000 -0.7500 -0.5800 -0.2300 0.0800 0.4300 -
Capex 1 20 3.23 3.88 3.77 7.44 5.16 5.15 7.29
Capex / Sales 10.98% 1.24% 1.27% 1.14% 1.86% 1.01% 0.8% 0.86%
Announcement Date 3/2/20 3/1/21 2/24/22 3/1/23 2/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
9.57 USD
Average target price
17.3 USD
Spread / Average Target
+80.77%
Consensus
  1. Stock Market
  2. Equities
  3. FOLD Stock
  4. Financials Amicus Therapeutics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW